Tarsus to Host Webcast to Review Topline Results from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis
04/29/2022 - 09:23 PM
IRVINE, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, will hold a webcast on Monday, May 2, 2022 at 5:00am PT/8:00am ET to review the topline results from the Saturn-2 Phase 3 trial for TP-03 (lotilaner ophthalmic solution, 0.25% ) for the treatment of Demodex blepharitis and provide a brief corporate update.
Webcast Information
The webcast can be accessed at the events section of the Tarsus website. After the live webcast, the event will remain archived on the Tarsus website at https://ir.tarsusrx.com/ for 90 days.
About Tarsus Pharmaceuticals, Inc. Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. The company is studying two investigational medicines in clinical trials. Its lead product candidate, TP-03, is a novel therapeutic being studied in a second Phase 3 pivotal trial for the treatment of Demodex blepharitis. TP-03 is also being developed for the treatment of Meibomian Gland Disease. In addition, Tarsus is developing TP-05, an oral, non-vaccine therapeutic for the prevention of Lyme disease, which is currently being studied in a Phase 1b clinical trial.
Contacts: Media Contact: Adrienne Kemp Sr. Director, Corporate Communications (949) 922-0801akemp@tarsusrx.com
Investor Contact: David Nakasone Head of Investor Relations (949) 620-3223DNakasone@tarsusrx.com
Tarsus Pharmaceuticals Inc
TARS Rankings
#3621 Ranked by Stock Gains
TARS Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Medicinal and Botanical Manufacturing
About TARS
tarsus pharmaceuticals, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. its lead product candidate is tp-03, a novel therapeutic that is in phase iib/iii for the treatment of blepharitis caused by the infestation of demodex mites, as well as to treat meibomian gland disease. the company is also developing tp-04 for the treatment of rosacea; and tp-05 for lyme prophylaxis and community malaria reduction. tarsus pharmaceuticals, inc. was founded in 2016 and is headquartered in irvine, california.